SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-18-009595
Filing Date
2018-04-27
Accepted
2018-04-27 16:30:14
Documents
6
Period of Report
2018-06-08
Effectiveness Date
2018-04-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A bold-def14a_20180608.htm DEF 14A 582672
2 GRAPHIC g2018042718353453225329.jpg GRAPHIC 47017
3 GRAPHIC g2018042718353450725328.jpg GRAPHIC 48924
4 GRAPHIC g2018042718353066125325.jpg GRAPHIC 3765
5 GRAPHIC g2018042718353066825326.jpg GRAPHIC 2052
6 GRAPHIC g2018042718353068025327.jpg GRAPHIC 2052
  Complete submission text file 0001564590-18-009595.txt   727464
Mailing Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108
Business Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108 415-638-6556
Audentes Therapeutics, Inc. (Filer) CIK: 0001628738 (see all company filings)

IRS No.: 461606174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37833 | Film No.: 18784395
SIC: 2836 Biological Products, (No Diagnostic Substances)